Is Wegovy or Zepbound better for weight loss?
Medically reviewed by: Dr. Alexandra Christiansen, MD
Written by: Azhar Qureshi
Helimeds’ Fact-Checking Standards. Every piece of content at Helimeds adheres to the highest editorial standards for language, style, and medical accuracy. To learn what we do to deliver the best health insights to you, check out our content review principles.
Zepbound produced greater average weight loss than Wegovy in a direct comparison of their weekly injections. After 72 weeks, participants taking Zepbound lost an average of 20.2% of their starting body weight, compared with 13.7% for those taking Wegovy. The Wegovy doses in that comparison were no higher than 2.4 mg. Read the trial comparison. (mavenclinic.com)
That result does not mean Zepbound is the better choice for everyone. The study average cannot predict an individual result, and the choice also depends on medical history, side effects, other treatment goals and cost. A licensed provider can help you weigh those factors before you choose a medication.
What the weight-loss comparison means
The head-to-head trial included adults with obesity or overweight and a weight-related condition. Participants did not have type 2 diabetes. Both groups received weekly injections, and the results were measured over 72 weeks. (pubmed.ncbi.nlm.nih.gov)
The difference between the averages was 6.5 percentage points of starting body weight. For perspective, on a starting weight of 200 pounds, those percentages correspond to about 40 pounds and 27 pounds, respectively. That is only an illustration of the averages, not a prediction of what an individual will lose.
There are also limits to what the comparison tells us:
- The results are group averages. Some people respond more or less than the average on either medication.
- The comparison took time. It does not establish how quickly any individual will lose weight.
- It did not compare every formulation or dose. A higher-dose Wegovy injection has been studied separately, but it was not part of this head-to-head comparison. Results from different trials cannot be compared as reliably as results from the same trial. The comparison of the medications describes the higher-dose study as a separate trial. (mavenclinic.com)
If you have type 2 diabetes or other health conditions, ask your provider how the available evidence applies to you rather than treating the trial averages as a personal target.
How Wegovy and Zepbound differ
Wegovy contains semaglutide, which acts on the glucagon-like peptide-1, or GLP-1, pathway. Zepbound contains tirzepatide, which acts on both GLP-1 and glucose-dependent insulinotropic polypeptide, or GIP, pathways. Both medications affect appetite and fullness. As UCHealth explains, the medications work in related but distinct ways. (uchealth.org)
The trial compared weekly injections of both drugs. Wegovy also has an oral form, but the injection comparison above does not tell us how that pill compares directly with Zepbound. If avoiding injections matters to you, discuss the available formulations and their suitability with your provider.
Both medications are used alongside a reduced-calorie eating plan and physical activity. A practical plan should also account for nutrition, tolerability and how you will maintain care over time.
Other health goals can affect the choice
Weight loss is one part of the decision. The medications have different FDA-approved uses that may matter when a provider reviews your health history.
- Wegovy is also approved to reduce the risk of major cardiovascular events in certain adults with established cardiovascular disease and overweight or obesity. (accessdata.fda.gov)
- Zepbound is also approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity. (accessdata.fda.gov)
These indications do not mean either medication is appropriate for everyone with heart disease or sleep apnea. They give you and your provider another reason to discuss your full health picture. Novant Health’s overview compares these additional uses.
Side effects and safety considerations
Both medications can cause digestive side effects, including nausea, vomiting, diarrhea and constipation. Side effects can influence which treatment a person can tolerate, but the head-to-head average does not establish that one will be easier for you personally. (uchealth.org)
Both drugs have boxed warnings about thyroid C-cell tumors. They should not be used by people with a personal or family history of medullary thyroid cancer or with multiple endocrine neoplasia syndrome type 2, known as MEN2. UCHealth discusses the thyroid warning and other Zepbound precautions. (accessdata.fda.gov)
Before starting either medication, tell your provider about your health history and everything you take. In particular, discuss:
- A history of pancreatitis, gallbladder problems or significant digestive problems
- Diabetes medications and other prescriptions or supplements
- Pregnancy, breastfeeding or plans to become pregnant
- Use of oral birth control, because tirzepatide can affect its absorption (accessdata.fda.gov)
If you develop severe or persistent abdominal pain, or repeated vomiting that makes it difficult to stay hydrated, seek prompt medical care. Contact your prescriber about troublesome side effects rather than changing or stopping a medication on your own.
Cost, access and longer-term planning
The medication with the larger trial average may not be the most practical choice if you cannot obtain or continue it. Insurance coverage varies by plan, medication and reason for treatment. Ask your insurer or pharmacy whether either drug is covered, whether prior authorization is needed and what your expected out-of-pocket costs would be.
Consider the total cost of care, not just the medication. Depending on the arrangement, consultations and other services may be separate. Check current treatment information rather than relying on an advertised price or assuming a particular inclusion.
Weight management is also a longer-term decision. Discuss follow-up, nutrition, physical activity and what happens if treatment needs to change. If you have concerns about your response, side effects or coverage, a provider can assess whether a change is appropriate. Do not switch between Wegovy and Zepbound or take them together without a prescriber’s guidance.
What about compounded semaglutide or tirzepatide?
Wegovy and Zepbound are FDA-approved branded medications. Compounded medications, including compounded semaglutide and compounded tirzepatide, are not FDA-approved and should not be described as equivalent to or interchangeable with those brands. The branded trial results above do not establish how a particular compounded preparation will perform. (helimeds.com)
If you are considering a compounded option, ask your provider what is being prescribed, why it is appropriate for you and how it differs from a branded medication. Helimeds offers weight-management pathways that may include branded or compounded treatment, subject to clinical review and state availability.
Choosing your next step
If average weight loss is your main question, Zepbound had the stronger result in the 72-week injection trial. If your priority also includes cardiovascular health, sleep apnea, tolerability or reliable access, those factors deserve equal attention in the decision.
You can begin a Helimeds consultation to discuss your medical history and treatment options. Complete a medical intake and consult with a licensed provider. If clinically appropriate, treatment may be prescribed and fulfilled through a licensed pharmacy partner, subject to state availability and medical review.
History
Current Version
Written by Azhar Qureshi
Medically reviewed by Dr. Alexandra Christiansen, MD






